Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer
- PMID: 21123638
- PMCID: PMC2996153
- DOI: 10.4065/mcp.2010.0414
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer
Abstract
Women with a germline BRCA1 or BRCA2 mutation or a hereditary predisposition for breast and ovarian cancer have substantial risk of breast or ovarian cancer relative to the general US population. Health care professionals can be instrumental in identifying women at increased risk through obtaining a comprehensive family history and becoming familiar with family history characteristics associated with hereditary predisposition for breast and ovarian cancer. BRCA carriers and women at very high risk benefit from multidisciplinary, individualized medical evaluation and risk management. We conducted a search of MEDLINE from 1989 through 2010 for the terms BRCA1, BRCA2, breast cancer, ovarian cancer, risk assessment, and genetic testing. We reviewed abstracts and relevant randomized and prospective studies that included very high-risk patient groups and BRCA mutation carriers. Herein, we review the role of genetic consultation and BRCA testing and the comprehensive, multisystem recommendations for risk management. A multidisciplinary approach offers the ability to educate those at very high risk about cancer prevention, reduce cancer risk, maximize early detection of breast and ovarian cancer, and improve survival.
Similar articles
-
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987. JAMA. 2019. PMID: 31429903
-
Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Breast Cancer Res Treat. 2016 Dec;160(3):393-410. doi: 10.1007/s10549-016-4003-9. Epub 2016 Oct 12. Breast Cancer Res Treat. 2016. PMID: 27734215 Review.
-
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145
-
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.Ann Ital Chir. 2019;90:1-2. Ann Ital Chir. 2019. PMID: 30872561
-
[Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers].Med Clin (Barc). 2007 Mar 31;128(12):468-76. doi: 10.1157/13100569. Med Clin (Barc). 2007. PMID: 17408542 Review. Spanish.
Cited by
-
Breast cancer genomic analyses reveal genes, mutations, and signaling networks.Funct Integr Genomics. 2024 Nov 4;24(6):206. doi: 10.1007/s10142-024-01484-y. Funct Integr Genomics. 2024. PMID: 39496981
-
The Effects of National Insurance Coverage Expansion and Genetic Counseling's Role on BRCA1/2 Mutation Tests in Breast Cancer Patients.Cancers (Basel). 2024 May 14;16(10):1865. doi: 10.3390/cancers16101865. Cancers (Basel). 2024. PMID: 38791944 Free PMC article.
-
Aberrant miR-3135b and miR-1273g-3p expression in the peripheral blood samples of BRCA1/2 (±) ovarian cancer patients.Heliyon. 2023 Dec 20;10(1):e23876. doi: 10.1016/j.heliyon.2023.e23876. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38234891 Free PMC article.
-
Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer.J Cancer. 2023 Oct 16;14(18):3397-3403. doi: 10.7150/jca.89082. eCollection 2023. J Cancer. 2023. PMID: 38021157 Free PMC article.
-
Early signs of cancer present in the fine detail of mammograms.PLoS One. 2023 Apr 5;18(4):e0282872. doi: 10.1371/journal.pone.0282872. eCollection 2023. PLoS One. 2023. PMID: 37018164 Free PMC article.
References
-
- Lindor NM, McMaster ML, Lindor CJ, Greene MH, National Cancer Institute. Division of Cancer Prevention. Community Oncology and Prevention Trials Research Group Concise handbook of familial cancer susceptibility syndromes: second edition. J Natl Cancer Inst Monogr. 2008;2008(38):1-93 - PubMed
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249 - PubMed
-
- ACOG The American Congress of Obstetricians and Gynecologists Web site. Washington, DC: American Congress of Obstetricians and Gynecologists ACOG; http://www.acog.org/from_home/proxy/ Accessed September 20, 2010
-
- Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4(9):665-676 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
